Overview

Affibody is a Swedish biotechnology company developing next generation biologics based on the company’s unique proprietary technology platform. Affibody^® molecules are a novel drug class of small therapeutic proteins with characteristics which may offer substantial advantages over monoclonal antibodies (mAbs) and antibody fragments.

Affibody aims to improve the lives of patients with serious diseases. We focus on indications and target proteins where our technology platform offers us a competitive advantage and where there is a high unmet medical need in well-defined patient populations. We run pre-clinical and clinical development programs in immunology and oncology.

In immunology, several clinical studies are underway together with our partners ACELYRIN and Rallybio – with izokibep in IL-17 mediated diseases and with RLYB116 in complement mediated diseases.

The clinical results with izokibep have validated the potential of the platform to generate miniaturized multispecific protein drugs that address unmet medical needs.

In asthma, we are developing a drug candidate targeting TSLP, a cytokine shown to play a central role in the underlying inflammatory processes in moderate and severe asthma. The drug candidate has properties that offer the potential to develop into a long-acting inhaled treatment with efficacy superior to other compounds in its class. In addition, Affibody is collaborating with Chiesi to discover and develop novel Affibody^® molecules as innovative treatments for respiratory diseases.

In fibrotic diseases, Affibody’s partner Antaros is developing a new PET tracer, ATH001, to probe the presence of platelet-related growth factor receptor beta (PDGFRβ), which is a marker of ongoing fibrogenesis in tissue. This PET diagnostic program complements our therapeutic programs in immunology.

In oncology, we have demonstrated that Affibody^® molecules can effectively target HER2-expressing tumors in patients with metastatic disease. Supported by our advanced imaging diagnostic, we are developing a radiation based targeted precision drug for patients who no longer respond to existing treatments.

To complement Affibody’s proprietary radiopharmaceutical development, Affibody’s partner GE Healthcare is also developing a PET imaging candidate, GE-226, with a view to improve the diagnosis of HER2-positive cancers. GE-226 is a Fluorine-18-labeled Affibody^® molecule that binds to HER2.

Affibody is continuously employing its technology platform across immunology and oncology indications with the aim of running enough discovery projects to enable at least one and potentially two candidate drug (CD) selections per year. Affibody will continue to apply its expertise in selectively advancing clinical programs and assessing market opportunities based on each project’s indication and partnership potential.